Imdelltra (tarlatamab-dlle)

P2, N=252, Active, not recruiting, Amgen | Recruiting --> Active, not recruiting

Concurrent radiotherapy with tarlatamab is safe, with low severe toxicity, frequent local tumor response, and a trend toward improved OS, supporting further study in ES-SCLC.

By sharing insights into administration protocols, dose ramp-up procedures, post-cycle 1 monitoring, and AE management strategies implemented at their centres, early adopters of tarlatamab can help other institutions develop and refine their own protocols more efficiently. Lessons learned during the early implementation phase, including the roles of various healthcare providers and the transition from inpatient to outpatient care, should facilitate the smoother integration of tarlatamab and other TCEs for solid tumours into clinical pathways across Canada.

P1/2, N=40, Recruiting, Institut Gustave Roussy

P2/3, N=129, Recruiting, Intergroupe Francophone De Cancerologie Thoracique

P2/3, N=129, Recruiting, Amgen Inc.

P1/2, N=87, Recruiting, Grupo Espanol De Tumores Neuroendocrinos

P1, N=47, Recruiting, Amgen Inc.

P1/2, N=57, Not yet recruiting, AIO-Studien gGmbH

P3, N=129, Recruiting, Intergroupe Francophone de Cancerologie Thoracique | Not yet recruiting --> Recruiting | Trial completion date: Mar 2030 --> Aug 2030 | Initiation date: Sep 2025 --> Feb 2026 | Trial primary completion date: Sep 2028 --> Feb 2029

P2, N=34, Not yet recruiting, Maastricht University Medical Center

For unresectable, locally advanced disease, concurrent chemoradiation with etoposide-cisplatin followed by consolidation durvalumab is recommended, although the optimal dose-fractionation and the duration of consolidation immunotherapy remain to be investigated. Among the most promising emerging treatment strategies are DLL3-targeting therapies, buoyed by the recent success of tarlatamab in SCLC. The evolving role of molecular profiling in prognostication and treatment decision-making is also examined.